金域医学涨2.05%，成交额8056.58万元，主力资金净流入257.97万元

Core Viewpoint - The stock of Kingmed Diagnostics has shown a positive trend with a 15.57% increase year-to-date, despite a recent decline in revenue and profit margins [1][2]. Group 1: Stock Performance - On November 18, Kingmed Diagnostics' stock rose by 2.05%, reaching 30.80 CNY per share, with a trading volume of 80.57 million CNY and a turnover rate of 0.58%, resulting in a total market capitalization of 14.268 billion CNY [1]. - Year-to-date, the stock has increased by 15.57%, with a 2.98% rise over the last five trading days and a 7.77% increase over the last 20 days, while it has decreased by 0.77% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion CNY, representing a year-on-year decrease of 19.23%, and a net profit attributable to shareholders of -796.095 million CNY, a decline of 184.84% [2]. - The company has distributed a total of 2.545 billion CNY in dividends since its A-share listing, with 1.647 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kingmed Diagnostics was 41,700, a decrease of 1.60% from the previous period, with an average of 11,042 circulating shares per shareholder, an increase of 1.62% [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 35.5057 million shares, a reduction of 2.8676 million shares from the previous period [3].